Etersalate is a derivative of aspirin exerting antiplatelet, analgesic, anti-inflammatory and antipyretic properties. Etersalate has potential to prevent oligomerization of amyloid beta (Aβ) peptides.

Levophacetoperane is a piperidine derivative. Levofacetoperane is a sympathomimetic central nervous system stimulant and is commonly used to treat depression. Levophacetoperane is also a known analeptic and is strongly linked to apnea reversal in dogs after a single intravenous injection.

Cefcanel is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcanel is active against the species E. coli, K. aerogenes and Proteus mirabilis; H. influenzae and M. catarrhalis has reasonable susceptibility. Cefcanel inhibits 90% of S. aureus strains at 2 µg/ml, irrespective of the presence of a β-lactamase. Cefcanel binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Sovaprevir (formerly ACH-1625) is an oral, once-daily, small molecule inhibitor of HCV protease being developed by Achillion Pharmaceuticals for the treatment of Hepatitis C. ACH-1625 is a linear peptidomimetic inhibitor that non-covalently binds to HCV NS3 protease with high potency and specificity. Short-term monotherapy of HCV genotype-1 infection with ACH-1625 was found to be safe and resulted in ≥3.3 log(10) IU/ml mean viral load reduction. Sovaprevir was developed as a therapy for patients with chronic HCV. Approximately 550 patients already have been treated with the drug in two phase 2 studies with 12-week treatment programs. One study included treatment with sovaprevir combined with pegylated interferon and ribavirin, and the other monitored the use of sovaprevir in combination with ACH-3102, Achillions second-generation NS5A inhibitor. In the second study, all of the patients with HCV genotype 1b achieved sustained virologic response.

Livoletide (AZP-531) is an analog of unacylated ghrelin, a naturally occurring hormone that is thought to counteract the effects of acylated ghrelin. The drug was designed to improve glycaemic control and reduce weight. Livoletide participated in pivotal phase 2b/3 clinical study for the treatment of Prader-Willi syndrome. In addition, the drug was studied in patients with type 2 diabetes mellitus (T2D). Its pharmacokinetic profile, suitable for once daily dosing, and metabolic effects support further clinical development for T2D.

Vapendavir (BTA-798) is an orally active capsid-binding inhibitor. It is a potent, orally bioavailable, broad spectrum inhibitor of the large group of HRVs. Vapendavir binds tightly to VP1s canyon and disrupts the ability of the capsid to bind to a specific cell surface receptor. This further inhibits the release of the viral RNA into the cell cytoplasm during the viral uncoating process (removing the lipid bilayer), thereby disrupting viral replication. Vapendavir is designed to be dosed orally. Vapendavir is in phase II clinical trials for the treatment of rhinovirus-induced aggravation of pre-existing asthma or COPD. Vapendavir has shown significant results in proof-of-concept studies. Thus far, from the Phase 1/2 studies conducted, vapendavir has demonstrated a desirable clinical pharmacology profile with high bioavailability, linear pharmacokinetic profile, remained unaffected by concomitant medications, and was not exclusively metabolized.

Delergotrile is a derivative of ergot alkaloids with dopaminergic and anti-parkinsonian action. Delergotine shows neuropharmacological action typical of postsynaptic dopamine D1 receptor stimulants, in particular in the extrapyramidal system. In addition, delergotine stimulates adenylate cyclase coupled serotonin receptors and antagonize central alpha-adrenergic receptors. The compound was studied in the clinical trials, in new, non-levodopa-treated parkinsonian patients. Delergotine elicited a significant but mostly only mild or moderate antiparkinsonian efficacy which seems to be less than that of levodopa.

Meseclazone (W-2395) is a non-steroidal anti-inflammatory drug. It exerts anti-inflammatory, analgesic and antipyretic activity. Meseclazone inhibits in vitro and ex vivo platelet aggregation initiated by the release reaction. It inhibits bradykinin-induced bronchospasm.